Cepheid Launches TB Test under CE IVD Directive | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid today said that it has launched its Xpert MTB/RIF test as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices.

The test, which runs on the firm's GeneXpert System, simultaneously identifies Mycobacterium tuberculosis and resistance to first-line drug therapy rifampicin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.